Ian Mortimer shared insights on lead NAV1.7 candidate's clinical profile, confident in its testing on humans. XOL studies use actual placebo rates for statistical modeling, mitigating risks. AES meeting will focus on 36-month data showing seizure reduction consistency.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay